<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878692</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0519</org_study_id>
    <nct_id>NCT04878692</nct_id>
  </id_info>
  <brief_title>Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies</brief_title>
  <acronym>OPERA</acronym>
  <official_title>Evaluation of a Cosmetic Product (Onco-Rash) to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies Which Are Known to Fragilize Epidermis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is important for patients treated with anti-EGFR therapies to get access to cosmetic&#xD;
      options to preserve their skin condition during treatment. Anti-EGFR therapies are known to&#xD;
      fragilize epidermis and to provoke rashes; which often lead to treatment discontinuation.&#xD;
&#xD;
      The aim of this study is to demonstrate that the Onco-Rash cream is able to preserve skin&#xD;
      condition without side effects. Decreasing skin toxicity is expected to improve patients'&#xD;
      life and facilitate treatment follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the percentage of Onco-Rash failure by counting the number of patients with a rash grade ≥ 2 (NCI-CTCAE scale).</measure>
    <time_frame>6 weeks after the start of the anti-EGFR treatment.</time_frame>
    <description>Measurement of Onco-Rash percentage of failure by counting the number of patients for whom a skin rash with a grade ≥ 2 (NCI-CTCAE scale) will occur between 0-6 weeks after the start of the anti-EGFR treatment. The introduction of an anti-inflammatory, a calming or an antibiotic treatment for acne will also be considered as failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timing of apparition of grade 1, 2 or ≥ 2 skin eruption: number of days between the start of the anti-EGFR treatment and the apparition of a skin eruption.</measure>
    <time_frame>6 weeks after the start of the anti-EGFR treatment.</time_frame>
    <description>Comparison of timing of apparition of grade 1, 2 or ≥ 2 skin eruption between the Onco-Rash arm and the Onco-Neutral arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a grade 1, 2 or ≥ 2 skin eruption</measure>
    <time_frame>6 weeks after the start of the anti-EGFR treatment.</time_frame>
    <description>Number of patients for whom a grade 1, 2 or ≥ 2 skin eruption have been reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients for whom treatment for acne (anti-inflammatory or antibiotic) has been introduced</measure>
    <time_frame>6 weeks after the start of the anti-EGFR treatment.</time_frame>
    <description>Number of patients for whom treatment for acne (anti-inflammatory or antibiotic) has been prescribed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Onco-Rash arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm label, patients will apply the Onco-Rash cream on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.&#xD;
This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Onco-Neutre arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this arm label, patients will apply the Onco-Neutre cream on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.&#xD;
Onco-Neutral cream will be used as an experimental comparator to Onco-Rash cream.&#xD;
This arm will be compared to the Onco-Neutral arm, in which the Onco-Neutral cream will be applied on selected zones (face, neck, thorax,…) twice a day, during 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Application of Onco-Rash cream</intervention_name>
    <description>The cream &quot;Onco-Rash&quot; will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage.</description>
    <arm_group_label>Onco-Rash arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Application of Onco-Neutre cream</intervention_name>
    <description>The cream &quot;Onco-Neutre&quot; will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage.</description>
    <arm_group_label>Onco-Neutre arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient &gt; 18 years old&#xD;
&#xD;
          -  Patient naive from anti-EGFR treatment (gefitinib, erlotinib, afatinib, cetuximab&#xD;
             panitumumab, osimertinib, alectinib et crizotinib, etc).&#xD;
&#xD;
          -  NSCLC (non-small cell lung cancer) patients eligible to anti-EGFR as first line&#xD;
             treatment (gefitinib, erlotinib,afatinib, etc)&#xD;
&#xD;
          -  Colorectal cancer patients eligible to anti-EGFR as first line treatment (cetuximab,&#xD;
             panitumumab,….)&#xD;
&#xD;
          -  Head and Neck/ENT (Ear, Nose Troat) cancer patients eligible to anti-EGFR as first&#xD;
             line treatment (cetuximab,…)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Social security affiliation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or Breastfeeding patient&#xD;
&#xD;
          -  Patient in age to procreate without an efficient contraceptive method&#xD;
&#xD;
          -  Patient with previous experience of allergic or irritative contact dermatitis to&#xD;
             components of the studied product&#xD;
&#xD;
          -  Patient with dermatologic conditions that cannot permit the study of skin toxicity of&#xD;
             anti-EGFR&#xD;
&#xD;
          -  Patients under radiotherapy 8 days prior the inclusion date&#xD;
&#xD;
          -  Patient under immunotherapy 8 days prior the inclusion date&#xD;
&#xD;
          -  Patient with local or systemic antibiotic treatment for acne 8 days prior the&#xD;
             inclusion date&#xD;
&#xD;
          -  Patient with antihistamines treatment 8 days prior the inclusion date&#xD;
&#xD;
          -  Patients taking NSAIDs or corticoids as chronic medication or that took NSAIDs or&#xD;
             corticoids 5 days prior the inclusion date&#xD;
&#xD;
          -  Participation to another interventional study&#xD;
&#xD;
          -  Patient with an altered ECOG (Eastern Cooperative Oncology Group) state ( &gt;2)&#xD;
&#xD;
          -  Patient deprived of liberty or subjected to guardianship&#xD;
&#xD;
          -  Impossibility to track and follow patient for geographical, social or psychiatric&#xD;
             reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien PERON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie des Hospices Civils de Lyon - Service d'Oncologie médicale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien PERON, MD</last_name>
    <phone>478862339</phone>
    <phone_ext>+33</phone_ext>
    <email>julien.peron@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Sophie BELMONT</last_name>
    <phone>0478864195</phone>
    <phone_ext>+33</phone_ext>
    <email>anne-sophie.belmont@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie des Hospices Civils de Lyon - Service Oncologie Médicale - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julien PERON, MD</last_name>
      <phone>478862339</phone>
      <phone_ext>+33</phone_ext>
      <email>julien.peron@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Sophie BELMONT</last_name>
      <phone>478864195</phone>
      <phone_ext>+33</phone_ext>
      <email>anne-sophie.belmont@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin Rash</keyword>
  <keyword>anti-EGFR therapy</keyword>
  <keyword>Cosmetic Product</keyword>
  <keyword>Acne</keyword>
  <keyword>Cancer patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

